

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Netarsudil-latanoprost for previously treated primary open-angle glaucoma or ocular hypertension [ID1363]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

During consultation it was highlighted that glaucoma risk differs between ethnic groups. However, the consultees noted that there is likely to be limited data available on the risk of glaucoma in different ethnic groups.

The NICE technical team also notes that:

- Glaucoma more commonly affects people over the age of 70. This group has an increased likelihood of polypharmacy and potential adverse drug interactions
- People with cognitive and/or physical impairments or learning disabilities may require specific consideration in terms of decisions about the diagnosis, management and treatment of glaucoma
- People who are pregnant or breastfeeding may need specific consideration in terms of discussions about management and pharmacological treatment.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The committee will consider whether its recommendations could have a different impact on people protected by the equality legislation than on the

wider population.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

Not applicable.

**Approved by Associate Director (name):** Jasdeep Hayre

**Date:** 9 February 2023